Todd Brady

Dr. Brady has served as a member of the board of directors since Dec 2007. Dr. Brady has more than 18 years of pharmaceutical clinical and business development experience and is currently president and CEO of Aldeyra Therapeutics. Prior to joining Aldeyra, Dr. Brady was an entrepreneur-in-residence and principal at Domain Associates, where he led institutional financing in numerous biotechnology companies from 2004 to 2013. Prior to joining Domain, Dr. Brady was a co-founder and CEO of Phenome Sciences, a biotechnology firm he merged with Xanthus Pharmaceuticals (acquired by Antisoma), where he was later executive vice president of Strategic Development and Planning. Dr. Brady also worked as head of business development and medical director at Aderis Pharmaceuticals (acquired by Schwarz Pharma, now part of UCB). While at Xanthus and Aderis, Dr. Brady was a medical consultant on numerous pre-clinical programs and clinical programs in Phases I through IV, including Neupro, a drug now marketed for Parkinson’s Disease. Dr. Brady holds an M.D. from Duke University Medical School, a Ph.D. from Duke University Graduate School, and an A.B. from Dartmouth College.